EP1064379A2 - Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein - Google Patents

Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein

Info

Publication number
EP1064379A2
EP1064379A2 EP99924683A EP99924683A EP1064379A2 EP 1064379 A2 EP1064379 A2 EP 1064379A2 EP 99924683 A EP99924683 A EP 99924683A EP 99924683 A EP99924683 A EP 99924683A EP 1064379 A2 EP1064379 A2 EP 1064379A2
Authority
EP
European Patent Office
Prior art keywords
undef
prostate
nucleic acid
seq
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99924683A
Other languages
German (de)
English (en)
Inventor
Thomas Specht
Bernd Hinzmann
Armin Schmitt
Christian Pilarsky
Edgar Dahl
André ROSENTHAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DAHL, EDGAR, DR.
Hinzmann Bernd Dr
PILARSKY, CHRISTIAN, DR.
ROSENTHAL, ANDRE, PROF.
SPECHT, THOMAS, DR.
Original Assignee
Metagen Gesellschaft fur Genomforschung Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagen Gesellschaft fur Genomforschung Mbh filed Critical Metagen Gesellschaft fur Genomforschung Mbh
Priority to EP02090142A priority Critical patent/EP1236799A3/fr
Publication of EP1064379A2 publication Critical patent/EP1064379A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to human nucleic acid sequences from breast tumor tissue which code for gene products or parts thereof, their functional genes which code for at least one biologically active polypeptide and their use.
  • the invention further relates to the polypeptides obtainable via the sequences and their use.
  • Breast cancer is one of the main causes of death in women, and new therapies are needed to combat it. Therapies used so far, such as Chemotherapy, hormone therapy or surgical removal of the tumor tissue often do not lead to complete healing.
  • the cancer phenomenon is often associated with the over- or under-expression of certain genes in the degenerate cells, although it is still unclear whether these changed expression rates are the cause or the consequence of the malignant transformation. The identification of such genes would be an essential step in the development of new therapies for cancer.
  • ESTs are sequences of cDNAs, ie reverse-transcribed mRNAs, the molecules that reflect the expression of genes. The EST sequences are determined for normal and degenerate tissues. Various operators offer such databases commercially.
  • the ESTs in the LifeSeq database used here are typically between 150 and 350 nucleotides long. They represent an unmistakable pattern for a particular gene, although this gene is usually much longer (> 2000 nucleotides).
  • the nucleic acid sequences Seq are of particular interest. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155-159, 160-161.
  • the invention thus relates to nucleic acid sequences which encode a gene product or a part thereof, comprising a) a nucleic acid sequence selected from the group of nucleic acid sequences Seq. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155-159, 160-161
  • nucleic acid sequences mentioned under a) or c) an allelic variation of the nucleic acid sequences mentioned under a) or c) a nucleic acid sequence which is complementary to the nucleic acid sequences mentioned under a) or b).
  • the invention further relates to a nucleic acid sequence according to one of the sequences Seq. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155-159, 160-161 or a complementary or allelic variant thereof and the nucleic acid sequences thereof have a 90% to 95% homology to a human nucleic acid sequence.
  • the invention also relates to the nucleic acid sequences Seq. ID No. 2 to Seq. ID No. 67 and Seq. ID No. 149 to Seq. ID. 161 and Seq ID. 201-202, which are expressed in increased breast tumor tissue
  • the invention further relates to nucleic acid sequences comprising a part of the above-mentioned nucleic acid sequences, in such a sufficient size that they can be combined with the sequences Seq. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155- 159, 160-161 hybridize.
  • the nucleic acid sequences according to the invention generally have a length of at least 50 to 4500 bp, preferably a length of at least 150 to 4000 bp, in particular a length of 450 to 3500 bp.
  • expression cassettes can also be constructed in accordance with current process practice, with at least one on the cassette the nucleic acid sequences according to the invention together with at least one control or regulatory sequence generally known to the person skilled in the art, such as, for. B. a suitable promoter is combined.
  • the sequences according to the invention can be inserted in sense or antisense orientation.
  • Expression cassettes or vectors are to be understood: 1. bacterial, such as. B., phagescript, pBs, ⁇ X174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene), pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), like eukaryont, 2nd eukaryont.
  • Suitable control or regulatory sequence means suitable promoters.
  • Two preferred vectors are the pKK232-8 and the PCM7 vector.
  • the following promoters are specifically meant: lad, lacZ, T3, T7, gpt, lambda PR, trc,
  • the DNA sequences on the expression cassette can encode a fusion protein which comprises a known protein and a biologically active polypeptide fragment.
  • the expression cassettes are also the subject of the present invention.
  • the nucleic acid fragments according to the invention can be used to produce full-length genes.
  • the available genes are also the subject of the present invention.
  • the invention also relates to the use of the nucleic acid sequences according to the invention and the gene fragments obtainable from the use.
  • nucleic acid sequences according to the invention can be brought into host cells with suitable vectors in which the genetic information contained on the nucleic acid fragments, which is expressed, is located as a heterologous part.
  • the host cells containing the nucleic acid fragments are also the subject of the present invention.
  • Suitable host cells are e.g. B. prokaryotic cell systems such as E. coli or eukaryotic cell systems such as animal or human cells or yeasts.
  • the nucleic acid sequences according to the invention can be used in sense or antisense form.
  • the polypeptides or their fragments are produced by cultivating the host cells in accordance with common cultivation methods and then isolating and purifying the peptides or fragments, likewise by means of conventional methods.
  • the invention further relates to nucleic acid sequences which encode at least a partial sequence of a biologically active polypeptide.
  • the present invention relates to partial polypeptide sequences, so-called ORF (open reading frame) peptides, according to the sequence protocols Seq. ID No 71-79, 81-117, 119-121, 123, 126, 128-147, 162-168, 172, 174, 177-180, 183-185, 187, 190, 192-198.
  • ORF open reading frame
  • the invention further relates to the polypeptide sequences which have at least 80% homology, in particular 90% homology, to the polypeptide partial sequences according to the invention of Seq. ID No 71-79, 81-117, 119-121, 123, 126, 128-147, 162-168, 172, 174, 177-180, 183-185, 187, 190, 192-198.
  • the invention also relates to antibodies which are directed against a polypeptide or fragment thereof, which of the nucleic acids of the sequences Seq. ID No 71-79, 81-117, 119-121, 123, 126, 128-147, 162-168, 172, 174, 177-180, 183-185, 187, 190, 192-198.
  • Antibodies are to be understood in particular as monoclonal antibodies.
  • polypeptides according to the invention of the sequences Seq. ID No 71-79, 81-117, 119-121, 123, 126, 128-147, 162-168, 172, 174, 177-180, 183-185, 187, 190, 192-198 can also be used as a tool Finding drugs against breast cancer can be used, which is also the subject of the present invention.
  • the present invention also relates to the use of the nucleic acid sequences according to the sequences Seq. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155-159, 160-161 for the expression of polypeptides used as tools for finding drugs against breast cancer can be.
  • the invention also relates to the use of the polypeptide partial sequences Seq found.
  • the invention also relates to medicaments which have at least one polypeptide partial sequence Seq. ID No 71-79, 81-117, 119-121, 123, 126, 128-147, 162-168, 172, 174, 177-180, 183-185, 187, 190, 192-198 included.
  • the nucleic acid sequences according to the invention found can also be genomic or mRNA sequences.
  • the invention also relates to genomic genes, their exon and intron structure and their splice variants, obtainable from the cDNAs of the sequences Seq. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155-159, 160-161, and their use together with suitable regulatory elements, such as suitable promoters and / or enhancers.
  • suitable regulatory elements such as suitable promoters and / or enhancers.
  • nucleic acids according to the invention are used to screen genomic BAC, PAC and cosmid libraries and use complementary ones
  • BAC, PAC and cosmid clones specifically isolated human clones.
  • the BAC, PAC and cosmid clones isolated in this way are hybridized with the aid of fluorescence in situ hybridization to metaphase chromosomes and corresponding chromosome sections are identified on which the corresponding genomic genes lie.
  • BAC, PAC and cosmid clones are sequenced in order to elucidate the corresponding genomic genes in their complete structure (promoters, enhancers, silencers, exons and introns).
  • BAC, PAC and cosmid clones can be used as independent molecules for gene transfer (see FIG. 5).
  • the invention also relates to BAC, PAC and cosmid clones containing functional genes and their chromosomal localization, according to the sequences Seq. ID No 3, 7, 9, 15, 17, 18, 21, 25, 27, 33, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50.51, 52, 53, 54, 55, 57, 58, 59, 61, 62, 63, 65, 66, 67, 150-153, 155-159, 160-161 for use as a gene transfer vehicle.
  • nucleic acids nucleic acids are to be understood in the full invention: mRNA, partial cDNA, full length cDNA and genomic genes (chromosomes).
  • ORF Open Reading Frame, a defined sequence of amino acids that can be derived from the cDNA sequence.
  • Module domain of a protein with a defined sequence that represents a structural unit and occurs in different proteins
  • Fig. 1 shows the systematic gene search in the Incyte LifeSeq database.
  • 4a shows the determination of the tissue-specific expression via electronic Northern.
  • Figure 5 shows the isolation of BAC and PAC genomic clones.
  • the following examples explain the preparation of the nucleic acid sequences according to the invention without restricting the invention to these examples and nucleic acid sequences.
  • the consensus sequences were extracted again and finally assembled with the previous consensus sequences as well as the singletons and the sequences not included in the database at 4% mismatch.
  • the consensus sequences were formed and used with the singletons and failures as the basis for the tissue comparisons. This procedure ensured that, under the parameters used, all sequences represented mutually independent gene regions.
  • 2b1-2b4 illustrates the extension of the breast tumor tissue ESTs.
  • sequences of the respective tissues assembled in this way were then compared using the same program (FIG. 3).
  • all sequences of the first tissue were first entered in the database. (It was therefore important that these were independent of each other.)
  • all sequences of the second tissue were compared to all of the first.
  • the result was sequences that were specific for the first and second tissues as well as those that occurred in both. In the latter, the ratio of the frequency of occurrence in the respective tissues was evaluated. All programs related to the evaluation of the assembled sequences were developed in-house.
  • a partial DNA sequence S e.g. B. a single EST or a contig of ESTs are using a standard program for homology search, z. B. BLAST (Altschul, SF, Gish W., Miller, W., Myers, EW and Lipman, DJ (1990) J. Mol. Bio, 215, 403-410), BLAST2 (Altschul, SF, Madden, T. L, Schaffer, AA, Zhang, J., Zhang, Z., Miller, W. and Lipman, DJ (1997) Nucleic Acids Research 25 3389-
  • tissue-ordered (private or public) EST libraries which determines homologous sequences in various tissue-ordered (private or public) EST libraries.
  • FASTA Pearson, W.R. and Lipman, D.J. (1988) Proc. Natl. Acad. Sci. USA 852444-2448.
  • the (relative or absolute) tissue-specific occurrence frequencies of this partial sequence S determined in this way are referred to as electronic Northern blot.
  • Tim23 which is localized in the protein translocase complex of the inner mitochondrial membrane.
  • the result is as follows: Electronic Northern for SEQ. ID. NO: 16
  • Musculoskeletal system 0.0223 0.0480 0.46392.1554
  • Musculoskeletal system 0.0086 0.0180 0.47582.1015

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Séquences d'acide nucléique humain, ARNm, ADNc, séquences génomiques tirées de tissus de tumeurs du sein qui codent pour des gènes ou des parties desdits gènes, ainsi que leur utilisation. Les polypeptides pouvant être obtenus par l'intermédiaire desdites séquences et leur utilisation sont également décrits.
EP99924683A 1998-03-20 1999-03-19 Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein Withdrawn EP1064379A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02090142A EP1236799A3 (fr) 1998-03-20 1999-03-19 Séquences d'acides nucléiques humaines issues du tissu de tumeur du sein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19813839A DE19813839A1 (de) 1998-03-20 1998-03-20 Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe
DE19813839 1998-03-20
PCT/DE1999/000908 WO1999047669A2 (fr) 1998-03-20 1999-03-19 Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein

Publications (1)

Publication Number Publication Date
EP1064379A2 true EP1064379A2 (fr) 2001-01-03

Family

ID=7862724

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02090142A Withdrawn EP1236799A3 (fr) 1998-03-20 1999-03-19 Séquences d'acides nucléiques humaines issues du tissu de tumeur du sein
EP99924683A Withdrawn EP1064379A2 (fr) 1998-03-20 1999-03-19 Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02090142A Withdrawn EP1236799A3 (fr) 1998-03-20 1999-03-19 Séquences d'acides nucléiques humaines issues du tissu de tumeur du sein

Country Status (4)

Country Link
EP (2) EP1236799A3 (fr)
JP (1) JP2002506643A (fr)
DE (1) DE19813839A1 (fr)
WO (1) WO1999047669A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666539B2 (en) * 1990-03-13 1996-02-15 Minerals Technologies Inc. Rhombohedral calcium carbonate and accelerated heat-aging process for the production thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887081B1 (fr) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Kinase régulée par les glucocorticoides du sérum humain, une cible pour maladies rénales chroniques et néphropaties diabétiques
US6469140B1 (en) 1998-02-06 2002-10-22 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US6680167B2 (en) 1998-02-06 2004-01-20 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US6482933B1 (en) 1998-02-06 2002-11-19 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US6340576B1 (en) 1998-02-06 2002-01-22 Millennium Pharmaceuticals, Inc. Nucleic acid molecules related to card-4L and CARD-4S
US6033855A (en) 1998-02-06 2000-03-07 Millennium Pharmaceuticals, Inc. Genes encoding caspase recruitment domain polypeptides
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
WO2000065067A2 (fr) * 1999-04-23 2000-11-02 University Of Washington Polynucleotides, polypeptides specifiques a la prostate, et leurs procedes d'utilisation
US6756196B2 (en) * 1999-06-28 2004-06-29 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
WO2001000825A2 (fr) * 1999-06-30 2001-01-04 Chiron Corporation Polynucleotides et polypeptides du syndrome bardet-biedl des chromosomes humains 15 et 16 et procedes d'utilisation
CA2386476A1 (fr) * 1999-10-18 2001-04-26 Emory University Compositions du gene tms1 et procedes d'utilisation
US6911306B1 (en) 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
US7005499B1 (en) * 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
WO2001036644A2 (fr) * 1999-11-18 2001-05-25 Curagen Corporation Polypeptide du type cytokine regule par la proteine wnt et acides nucleiques codant ce polypeptide
FR2801318A1 (fr) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Nouvelle kinase liee aux integrines ilk-2
US20040115761A1 (en) * 1999-12-14 2004-06-17 Spaderna Steven Kurt Polypeptides and nucleic acids encoding same
CA2395832A1 (fr) 2000-01-25 2001-08-02 Genentech, Inc. Compositions et methodes de traitement de cancer
AU3392901A (en) * 2000-02-25 2001-09-03 Oxford Glycosciences Uk Ltd Proteins
JP2001275681A (ja) * 2000-03-31 2001-10-09 Junya Masumoto アポトーシス関連蛋白質、その抗体及びそのｄｎａ
ATE353974T1 (de) * 2000-04-03 2007-03-15 Corixa Corp Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
JP2004500851A (ja) * 2000-05-25 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド 薬物代謝酵素
US20040053292A1 (en) * 2000-11-15 2004-03-18 Jurg Tschopp Proteins and dna sequences underlying these proteins used for treating inflammations
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
WO2002078516A2 (fr) * 2001-03-30 2002-10-10 Corixa Corporation Compositions et methodes de traitement et de diagnostic de cancers
CA2442993C (fr) 2001-04-10 2011-10-11 Agensys, Inc. Acide nucleique et proteine correspondante intitule 158p3d2 utiles dans le traitement et la detection du cancer
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
JP2005536439A (ja) * 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
DE10345009A1 (de) * 2003-09-22 2005-06-30 Anke Dr. Ehlers Verwendung von Flamingo Antagonisten und/oder Agonisten zur Diagnose und Behandlung von Krebs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668267A (en) * 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
DE19811193A1 (de) * 1998-03-10 1999-09-16 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Prostatatumorgewebe
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9947669A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666539B2 (en) * 1990-03-13 1996-02-15 Minerals Technologies Inc. Rhombohedral calcium carbonate and accelerated heat-aging process for the production thereof

Also Published As

Publication number Publication date
EP1236799A3 (fr) 2003-05-02
DE19813839A1 (de) 1999-09-23
JP2002506643A (ja) 2002-03-05
EP1236799A2 (fr) 2002-09-04
WO1999047669A3 (fr) 2000-06-15
WO1999047669A2 (fr) 1999-09-23

Similar Documents

Publication Publication Date Title
EP1064379A2 (fr) Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein
EP0892809B1 (fr) Proteines et acides nucleiques fhit et procedes afferents
KR100631766B1 (ko) 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및그들의 용도
US20020193567A1 (en) Secreted proteins and polynucleotides encoding them
US20040034192A1 (en) Human proteins having hyprophobic domains and dnas encoding these proteins
EP1071775A2 (fr) Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
CA2264192A1 (fr) Proteines secretees et polynucleotides codant lesdites proteines
JPH07188294A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたは抗体を含有する薬学的組成物
WO1999053040A2 (fr) Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne
US20040248256A1 (en) Secreted proteins and polynucleotides encoding them
WO1994001557A1 (fr) Proteine induisant l'osteogenese
CA2327259A1 (fr) Molecules de regulateur de transcription humaine
US20020065394A1 (en) Secreted proteins and polynucleotides encoding them
US20010039335A1 (en) Secreted proteins and polynucleotides encoding them
EP0624645B1 (fr) Protéine humaine chondromoduline-I
WO1998055614A2 (fr) Proteines secretees et polynucleotides codant ces proteines
US6221841B1 (en) General receptors for phosphoinositides and uses related thereto
WO1999047655A2 (fr) Sequences d'acides nucleiques humains provenant de tissus mammaires sains
WO1998011216A1 (fr) Nouveau gene de semaphorine: semaphorine y
US6706869B1 (en) Map kinase phosphatases and polynucleotides encoding them
US20040038276A1 (en) Secreted proteins and polynucleotides encoding them
US20030096272A1 (en) Genes regulated by peroxisome proliferator-activated receptor gamma agonist
US20030044935A1 (en) Secreted proteins and polynucleotides encoding them
US6579700B1 (en) NPY family member
US20020132293A1 (en) Mammalian neuralized family transcriptional regulators and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000810

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: METAGEN PHARMACEUTICALS GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DAHL, EDGAR, DR.

Owner name: PILARSKY, CHRISTIAN, DR.

Owner name: SPECHT, THOMAS, DR.

Owner name: ROSENTHAL, ANDRE, PROF.

Owner name: HINZMANN, BERND, DR.

17Q First examination report despatched

Effective date: 20050131

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071002